Toshimi Iizuka, Takahiko Kagaya, K. Atsuda, Y. Yoshiyama
{"title":"用味觉传感器评价高附加值仿制药的味道","authors":"Toshimi Iizuka, Takahiko Kagaya, K. Atsuda, Y. Yoshiyama","doi":"10.11223/JARDE.9.152","DOIUrl":null,"url":null,"abstract":"152 INTRODUCTION The isosorbide dinitrate or mononitrate are used chiefly to treat angina pectoris, and used as the osmotic diuretics in Japan. Additionally, it is used as a treatment of the intracranial hypertension, the ocular hypertension, and Meniere's disease. ISOBIDE was approved and put on the market in Japan in 1968. ISOBIDE is raising plasma osmolality and shows a brain pressure descent action, an intraocular pressure descent action, an inner lymph pressure descent action of an ear, and a diuretic effect. Moreover, a brain tumor patient may be administered for the purpose of brain pressure descent. However, the taste of ISOBIDE is unpalatable in the one that sweetness, acidity, and bitterness existed together. Generally, a bad taste drug may resist taking medicine, the possibility that the effect of the drug therapy is not achieved is thought, and there is a possibility that a satisfactory therapeutic effect is not obtained. In a package insert, it is important to consider the taste to complete the drug therapy though the method to take by the dilution with water is adopted to secure the adherence of ISOBIDE. In Evaluation of the Taste of Value Added Generic Drugs by a Taste Sensor","PeriodicalId":16589,"journal":{"name":"Journal of oral tissue engineering","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of the Taste of Value Added Generic Drugs by a Taste Sensor\",\"authors\":\"Toshimi Iizuka, Takahiko Kagaya, K. Atsuda, Y. Yoshiyama\",\"doi\":\"10.11223/JARDE.9.152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"152 INTRODUCTION The isosorbide dinitrate or mononitrate are used chiefly to treat angina pectoris, and used as the osmotic diuretics in Japan. Additionally, it is used as a treatment of the intracranial hypertension, the ocular hypertension, and Meniere's disease. ISOBIDE was approved and put on the market in Japan in 1968. ISOBIDE is raising plasma osmolality and shows a brain pressure descent action, an intraocular pressure descent action, an inner lymph pressure descent action of an ear, and a diuretic effect. Moreover, a brain tumor patient may be administered for the purpose of brain pressure descent. However, the taste of ISOBIDE is unpalatable in the one that sweetness, acidity, and bitterness existed together. Generally, a bad taste drug may resist taking medicine, the possibility that the effect of the drug therapy is not achieved is thought, and there is a possibility that a satisfactory therapeutic effect is not obtained. In a package insert, it is important to consider the taste to complete the drug therapy though the method to take by the dilution with water is adopted to secure the adherence of ISOBIDE. In Evaluation of the Taste of Value Added Generic Drugs by a Taste Sensor\",\"PeriodicalId\":16589,\"journal\":{\"name\":\"Journal of oral tissue engineering\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2012-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of oral tissue engineering\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.11223/JARDE.9.152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of oral tissue engineering","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.11223/JARDE.9.152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of the Taste of Value Added Generic Drugs by a Taste Sensor
152 INTRODUCTION The isosorbide dinitrate or mononitrate are used chiefly to treat angina pectoris, and used as the osmotic diuretics in Japan. Additionally, it is used as a treatment of the intracranial hypertension, the ocular hypertension, and Meniere's disease. ISOBIDE was approved and put on the market in Japan in 1968. ISOBIDE is raising plasma osmolality and shows a brain pressure descent action, an intraocular pressure descent action, an inner lymph pressure descent action of an ear, and a diuretic effect. Moreover, a brain tumor patient may be administered for the purpose of brain pressure descent. However, the taste of ISOBIDE is unpalatable in the one that sweetness, acidity, and bitterness existed together. Generally, a bad taste drug may resist taking medicine, the possibility that the effect of the drug therapy is not achieved is thought, and there is a possibility that a satisfactory therapeutic effect is not obtained. In a package insert, it is important to consider the taste to complete the drug therapy though the method to take by the dilution with water is adopted to secure the adherence of ISOBIDE. In Evaluation of the Taste of Value Added Generic Drugs by a Taste Sensor